Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609221 | 0.87 | ABL1 (0.57) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| SCHEMBL5999668 | 0.84 | ABL1 (0.67) | NPC1RAB9AABL1BCRSRC | |
| SCHEMBL5732836 | 0.83 | SYK (0.61) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| SCHEMBL1927060 | 0.83 | ABL1 (0.80) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| SCHEMBL4903303 | 0.82 | ABL1 (0.66) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| Water SCHEMBL7817247 | 0.82 | SYK (0.59) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| SCHEMBL4904236 | 0.78 | ABL1 (0.58) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| SCHEMBL3257066 | 0.78 | SYK (0.49) | SMN1; SMN2NPC1RAB9AKDM4EABL1 | |
| SCHEMBL3599515 | 0.77 | ABL1 (0.65) | NPC1RAB9AABL1BCRPRKCA | |
| SCHEMBL5998979 | 0.77 | SYK (0.59) | SMN1; SMN2NPC1RAB9AKDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151096-B2 | Cyclic compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-12-19 | — | — | US | disclosed |
| US-20040235841-A1 | Cyclic compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2004-11-25 | — | — | US | disclosed |
| WO-2004078682-A2 | CYCLIC COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235841-A1 | Cyclic compounds and compositions as protein kinase inhibitors | CDK2, CDK5, CDK1 | SMN1; SMN2 2169/4885NPC1 3486/4885RAB9A 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.